Press Releases
These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
-
Apr 2, 2019
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune-modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, today announced that the first...
-
Mar 21, 2019- Dr. Manuel Hidalgo, MD, PhD as Strategic Advisor
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, announced new leadership appointments as...
-
Mar 14, 2019- Gilead collaboration results in cash infusion of $150M; first milestone payment of $7.5M triggered
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, provided a corporate update and reported...
-
Mar 13, 2019- FDA has accepted IND filing for AGEN1423
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, announced today that the FDA has...
-
Mar 8, 2019
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, will release its fourth quarter and...
-
Feb 19, 2019-- Agenus Conference Call and Live Webcast Scheduled for 11:00a.m. ET today --
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, announced today the launch of...
-
Feb 15, 2019
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, announced today that its...
-
Jan 29, 2019- The Biotech Electronic Security Token (BEST) is designed to be an innovative and transformative way to finance drug development through increasing liquidity, minimizing dilution, and improving capital allocation
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, announced today, the upcoming...
-
Jan 24, 2019
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, and adoptive cell therapies1, today announced the closing of its...
-
Jan 3, 2019- Bill & Melinda Gates Foundation invests ~$1M to develop novel technology for QS-21
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, announced today that the Bill...